We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $459M
1-Year Est. Return 93.97%
This Fund
S&P 500
This Quarter Est. Return
+33.31%
1 Year Est. Return
+93.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$459M
AUM Growth
+$347M
Cap. Flow
+$245M
Cap. Flow %
53.32%
Top 10 Hldgs %
63.7%
Holding
167
New
86
Increased
23
Reduced
20
Closed
38

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$30.6M
2
GS icon
Goldman Sachs
GS
+$30.2M
3
XOM icon
ExxonMobil
XOM
+$26.8M
4
GPN icon
Global Payments
GPN
+$26.4M
5
NVDA icon
NVIDIA
NVDA
+$25.8M

Top Sells

Rank Stock Value
1
ASX icon
ASE Group
ASX
+$3.89M
2
ASND icon
Ascendis Pharma A/S
ASND
+$2.71M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$2.01M
4
PFE icon
Pfizer
PFE
+$2M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.93M

Sector Composition

Rank Sector Weight
1 Miscellaneous 28.72%
2 Healthcare 18.58%
3 Financials 14.08%
4 Industrials 12.67%
5 Technology 12.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDN
126
Brandywine Realty Trust
BDN
$537M
$52K 0.01%
16,416
+5,716
+53% +$17.2K
SOC icon
127
Sable Offshore Corp
SOC
$909M
$50.6K 0.01%
+16,430
New +$209K
XRX icon
128
Xerox
XRX
$436M
$41.2K 0.01%
+13,164
New +$32.9K
XLP icon
129
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.5B
$24.9K 0.01%
300
-6,000
-95% -$501K
OSG
130
Octave Specialty Group
OSG
$224M
– –
-139,168
Closed -$647K
AMGN icon
131
Amgen
AMGN
$236B
– –
-4,934
Closed -$1.74M
APGE
132
DELISTED
Apogee Therapeutics
APGE
– –
-4,007
Closed -$337K
ASND icon
133
Ascendis Pharma A/S
ASND
$17.7B
– –
-11,828
Closed -$2.71M
ASX icon
134
ASE Group
ASX
$97.7B
– –
-179,512
Closed -$3.89M
AXGN icon
135
Axogen
AXGN
$2.6B
– –
-16,273
Closed -$539K
CGON icon
136
CG Oncology
CGON
$6.62B
– –
-3,370
Closed -$228K
DXCM icon
137
DexCom
DXCM
$33.2B
– –
-3,628
Closed -$228K
DYN icon
138
Dyne Therapeutics
DYN
$4.53B
– –
-17,213
Closed -$312K
EQH icon
139
Equitable Holdings
EQH
$14.4B
– –
-6,794
Closed -$252K
ERAS icon
140
Erasca
ERAS
$5.66B
– –
-24,847
Closed -$402K
EWZ icon
141
CALL
iShares MSCI Brazil ETF
EWZ
$8.6B
– –
-120,000
Closed -$4.61M
GDX icon
142
VanEck Gold Miners ETF
GDX
$30.7B
– –
-2,000
Closed -$184K
GILD icon
143
Gilead Sciences
GILD
$187B
– –
-11,961
Closed -$1.67M
GMAB icon
144
Genmab
GMAB
$20.7B
– –
-16,030
Closed -$430K
GOOG icon
145
Alphabet (Google) Class C
GOOG
$4.1T
– –
-300
Closed -$86.1K
IBRX icon
146
ImmunityBio
IBRX
$8.56B
– –
-41,005
Closed -$315K
INDA icon
147
iShares MSCI India ETF
INDA
$6.75B
– –
-500
Closed -$23.4K
IOVA icon
148
Iovance Biotherapeutics
IOVA
$3.98B
– –
-19,760
Closed -$69.4K
IWM icon
149
PUT
iShares Russell 2000 ETF
IWM
$81.2B
– –
-3,500
Closed -$867K
JNJ icon
150
Johnson & Johnson
JNJ
$663B
– –
-7,902
Closed -$1.93M
3 4 5
6
7

Similar funds

VIM
VELA Investment Management New Albany, Ohio $459M AUM 18.61% 1-Year Est. Return
AM
Atwater Malick Lancaster, Pennsylvania $459M AUM 37.25% 1-Year Est. Return
SSC
Syverson Strege & Co West Des Moines, Iowa $459M AUM 27.74% 1-Year Est. Return
RFN
RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return
PWS
Peterson Wealth Services South Ogden, Utah $459M AUM 42.99% 1-Year Est. Return
GCM
G2 Capital Management Columbus, Ohio $459M AUM 18.56% 1-Year Est. Return
CIM
Coleford Investment Management Toronto, Ontario, Canada $459M AUM 23.79% 1-Year Est. Return
RAG
RIA Advisory Group Des Moines, Iowa $460M AUM 29% 1-Year Est. Return

Arrowpoint Investment Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Arrowpoint Investment Partners held 167 positions worth $459M, up 308% from $113M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Arrowpoint Investment Partners deployed $245M of net new capital in Q2 2026, opening 86 new positions and adding to 23 existing holdings. Its largest new stake was Citigroup: 235,033 shares worth $32.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $2.01M trimmed.

  • Arrowpoint Investment Partners's largest Q2 2026 buy was Citigroup: 235,033 shares worth $32.9M.
  • Arrowpoint Investment Partners added most to Insmed in Q2 2026, an estimated $2.8M increase.
  • Arrowpoint Investment Partners's biggest Q2 2026 reduction was Ionis Pharmaceuticals, cutting an estimated $2.01M.
  • Arrowpoint Investment Partners fully exited ASE Group in Q2 2026, selling an estimated $3.89M.
  • Arrowpoint Investment Partners's ten largest holdings make up 64% of its $459M portfolio in Q2 2026.
  • Arrowpoint Investment Partners opened 86 new positions and closed 38 in Q2 2026.
  • Arrowpoint Investment Partners's portfolio value rose 308% quarter-over-quarter to $459M.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.